A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors

  • STATUS
    Recruiting
  • End date
    Dec 23, 2022
  • participants needed
    261
  • sponsor
    MedImmune LLC
Updated on 4 April 2021
cancer
measurable disease
progressive disease
pemetrexed
carboplatin
hormone therapy
pembrolizumab
programmed cell death 1 ligand 1
cancer treatment
solid tumors
cancer chemotherapy

Summary

The purpose of this study is to evaluate MEDI5752 in adult subjects with advanced solid tumors, when administered as a single agent or combined with chemotherapy.

Description

This is a phase 1, first-time-in-human, multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety and tolerability, and efficacy, pharmacokinetics and Immunogenicity of MEDI5752 in adult subjects with advanced solid tumors, when administered as a single agent or combined with chemotherapy.

Details
Condition Non-Small Cell Lung Cancer, Pulmonary Disease, Adenocarcinoma, urinary tract neoplasm, Malignant neoplasm of kidney, Nephropathy, Renal Cell Carcinoma, Lung Neoplasm, Bronchial Neoplasm, Kidney Disease (Pediatric), Selected Advanced Solid Tumors, Kidney Cancer, Lung Cancer, Malignant Adenoma, Kidney Disease, Lung Disease, Renal Cell Cancer, Renal Cancer, Urologic Cancer
Treatment carboplatin, Pembrolizumab, Pemetrexed, durvalumab, MEDI5752, Durvalumab [only applicable to some countries]
Clinical Study IdentifierNCT03530397
SponsorMedImmune LLC
Last Modified on4 April 2021

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note